美尔雅，多重利空来袭

Group 1: Financial Performance - ST Er Ya (600107) expects a net profit attributable to shareholders for 2025 to be between -135 million to -90 million CNY, compared to a loss of 68.1 million CNY in the previous year [1] - The projected operating revenue for 2025 is between 210 million to 260 million CNY, with core operating revenue (excluding unrelated business income) expected to be between 207 million to 257 million CNY, which is below 300 million CNY [1] - The decline in performance is attributed to a decrease in operating revenue due to the disposal of a subsidiary, resulting in a loss of approximately 30 million CNY in the pharmaceutical segment, and a decrease in clothing business revenue [1][7] Group 2: Regulatory Issues - The company and its actual controller, Zheng Jiping, received an administrative penalty from the Hubei Securities Regulatory Bureau for suspected violations of information disclosure laws [2] - ST Er Ya and Zheng Jiping were found to have engaged in non-operating fund occupation through related party transactions, amounting to 103.72 million CNY, which constitutes a violation of securities laws [3][4] - The company failed to disclose non-operating fund occupation in its annual and semi-annual reports, with amounts of 71.5 million CNY and 32.22 million CNY respectively, leading to significant omissions in financial reporting [4] Group 3: Market Performance - The company's stock price has experienced a significant decline of over 30% since late October last year, with the latest stock price at 6.01 CNY and a market capitalization of 2.16 billion CNY [8][9] - As of January 30, the stock closed up 5.07% at 6.01 CNY per share, with a total market value of 21.64 billion CNY [9]